Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. VAX-24 has forecasted sales of $21 million in the same year. billion and $812 million in 2028.
Let's personalize your content